CATEQUENTINIB for Small cell lung cancer: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 12 adverse event reports in the FDA FAERS database where CATEQUENTINIB was used for Small cell lung cancer.
Most Reported Side Effects for CATEQUENTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Myelosuppression | 84 | 25.9% | 5 | 35 |
| Off label use | 37 | 11.4% | 14 | 6 |
| Diarrhoea | 33 | 10.2% | 4 | 4 |
| Hypertension | 26 | 8.0% | 1 | 2 |
| Nausea | 26 | 8.0% | 3 | 1 |
| Vomiting | 26 | 8.0% | 2 | 1 |
| Rash | 25 | 7.7% | 3 | 3 |
| Thrombocytopenia | 24 | 7.4% | 2 | 0 |
| Fatigue | 23 | 7.1% | 2 | 0 |
| Anaemia | 22 | 6.8% | 3 | 0 |
| Decreased appetite | 22 | 6.8% | 2 | 3 |
| Leukopenia | 21 | 6.5% | 1 | 0 |
| Disease progression | 20 | 6.2% | 3 | 3 |
| Hypothyroidism | 20 | 6.2% | 2 | 3 |
| Neutropenia | 19 | 5.9% | 2 | 1 |
Other Indications for CATEQUENTINIB
Lung neoplasm malignant (41)
Non-small cell lung cancer (24)
Lung adenocarcinoma (20)
Small cell lung cancer extensive stage (19)
Oesophageal carcinoma (10)
Breast cancer (8)
Breast cancer metastatic (7)
Colorectal cancer metastatic (7)
Lung adenocarcinoma stage iv (7)
Ovarian cancer (7)
Other Drugs Used for Small cell lung cancer
ETOPOSIDE (2,514)
ATEZOLIZUMAB (2,107)
CARBOPLATIN (1,991)
DURVALUMAB (1,063)
CISPLATIN (787)
NIVOLUMAB (787)
IPILIMUMAB (474)
LURBINECTEDIN (351)
TARLATAMAB-DLLE (332)
IRINOTECAN (329)